Needham & Company downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Buy to Hold.Analsyt Alan Carr commented, "Lexicon reported $5.4M U.S. Xermelo ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Lexicon Pharmaceuticals (LXRX) PT Lowered to $25 at Stifel; 'Despite Slow Xermelo Progress, We Still Can’t Reconcile Valuation Here'February 22, 2018 5:20 PM Lexicon Pharma (LXRX) Tops Q4 EPS by 14c, Beats on RevenuesFebruary 22, 2018 7:19 AM Form 8-K LEXICON PHARMACEUTICALS, For: Feb 22February 22, 2018 7:08 AM Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business UpdateFebruary 22, 2018 7:01 AM